BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Reaction Biology Corp. Awarded National Institutes of Health (NIH) SBIR Grant For Kinase Radioisotope Microarray Screening Development


6/20/2006 10:31:29 AM

MALVERN, Pa., June 20 /PRNewswire/ -- Reaction Biology Corporation ("RBC") today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC's DiscoveryDot(TM) nanoliter screening platform.

Protein kinase dysfunction is a key factor in cancer, inflammation and diabetes. Screening and profiling kinase inhibitors has been a major research and development effort in the pharmaceutical industry. While screening kinase activity with radioisotope detection is considered by many in the drug-discovery industry to be the "gold standard" of kinase assays, use of the format is limited by expense and the difficulty of radioactive disposal. The DiscoveryDot(TM) platform uses only a fraction of the reagents compared to well plate methods.

"Due to our nano-scale format, the amount of radioisotope used in the process should be minimal," said RBC Chief Technology Officer Haiching Ma, Ph.D. "This should lead to far fewer disposal and handling problems, and reduced cost overall."

About Reaction Biology Corporation

Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity. Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency.

More information: http://www.reactionbiology.com

Reaction Biology Corporation, 1764 Litchfield Turnpike, Suite 203, Woodbridge, CT 06525

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

Reaction Biology Corporation

CONTACT: Haiching Ma, Chief Technology Officer of Reaction BiologyCorporation, +1-610-722-0247, or fax, +1-610-722-0246,haiching@reactionbiology.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES